Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Corbus Pharmaceuticals Holdings, Inc.: Amendment to Certificate of Incorporation to effect a 1-for-30 reverse stock split (effective 2023-02-14).
- Change
- charter amendment
- Effective
- 2023-02-14
Exact text from the filing
On February 9, 2023, the Board approved a 1-for-30 Reverse Stock Split (“Reverse Stock Split”) and the Company filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 AM Eastern Time on February 14, 2023 (the “Effective Time”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Corbus Pharmaceuticals Holdings, Inc. entered into Exclusive License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd. valued at $7.5 million (effective 2023-02-12).
- Action
- entry
- Agreement
- license
- Counterparty
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Value
- $7.5 million
- Effective
- 2023-02-12
Exact text from the filing
On February 12, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with CSPC Megalith Biopharmaceutical Co., Ltd. (“CSPC”), pursuant to which the Company received an exclusive license to obtain certain exclusive rights to develop and commercialize CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate targeting Nectin-4.
View on SEC.gov